Evidence map›Paper›PMID 37074208›Full record

ArticleJournal of immunology (Baltimore, Md. : 1950)2023

IL-18 Binding Protein-Producing Cells Attenuate Anemia in Murine Macrophage Activation Syndrome.

Mathilde Harel, Sébastien Fauteux-Daniel, Emiliana Rodriguez, Gaby Palmer, Cem Gabay

Open access · hybridAbstract read
In one paragraph

Article in Journal of immunology (Baltimore, Md. : 1950), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.5field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 10 citations in OpenAlex.

  1. Interleukin-18 armours antitumour immune effectors.Nature reviews. Immunology · 2026
    Review
  2. Review
  3. IL-18-Mediated Tumor Immune Evasion.Current issues in molecular biology · 2026
    Review
  4. Article
  5. Article
  6. Review
  7. Review
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 2 countries.

Mathilde HarelDivision of Rheumatology, Department of Medicine, University Hospitals, Geneva, Switzerland.
Sébastien Fauteux-DanielDivision of Rheumatology, Department of Medicine, University Hospitals, Geneva, Switzerland.
Emiliana RodriguezDivision of Rheumatology, Department of Medicine, University Hospitals, Geneva, Switzerland.
Gaby PalmerDivision of Rheumatology, Department of Medicine, University Hospitals, Geneva, Switzerland.ORCID 0000-0001-7567-1798
Cem GabayDivision of Rheumatology, Department of Medicine, University Hospitals, Geneva, Switzerland.ORCID 0000-0001-6853-3063
University of Geneva · CH

Funding

Swiss National Science Foundation 201269
6 · The paper itself

Abstract

IL-18 is a pleiotropic immunoregulatory cytokine of the IL-1 family. IL-18 has been identified as a potent IFN-γ inducer in synergy with IL-12 and IL-15 and thus as a powerful Th1 cell-polarizing cytokine. IL-18 activity is regulated by its naturally occurring soluble inhibitor IL-18 binding protein (IL-18BP), the production of which is stimulated by IFN-γ in a negative feedback loop. Circulating levels of IL-18BP are elevated, and unbound bioactive free IL-18 is thus not detectable in the circulation in physiologic conditions. However, emerging evidence indicates that the IL-18/IL-18BP balance could be dysregulated in macrophage activation syndrome (MAS), as mirrored by the presence of free IL-18 in the circulation of patients with MAS. Herein, we sought to identify IL-18BP-producing cells in a murine CpG-induced MAS model using IL-18BP knock-in tdTomato reporter mice. Endothelial cells, tissue-resident macrophages, and neutrophils appeared as major cellular sources of IL-18BP. We also identified extramedullary and medullary early erythroid progenitors as IL-18BP-producing cells in an IFN-γ-dependent manner. This finding suggests a novel regulation of IL-18 activity by erythroid precursors, which are likely involved in the prevention of the negative effects of IL-18 on erythropoiesis. Indeed, coherent in vivo and in vitro results indicate that IL-18 indirectly impairs erythropoiesis while favoring myelopoiesis and thus contributes to anemia associated with MAS and potentially with other IL-18-driven inflammatory diseases. In conclusion, IL-18BP production by endothelial cells, neutrophils, macrophages, and erythroid precursors attenuates the anemia associated with murine CpG-induced MAS.

Indexed as

AnemiaMacrophage Activation SyndromeAnimalsCarrier ProteinsCytokinesEndothelial CellsIntercellular Signaling Peptides and ProteinsInterleukin-18MiceCarrier ProteinsCytokinesIntercellular Signaling Peptides and ProteinsInterleukin-18interleukin-18 binding protein

Identifiers

PMID37074208
PMCPMC7614543
OpenAlexW4366351154

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.